For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

NRG GI005

Trial Overview

Official Title

Using Cancer Cells In the Blood (Ctdna) To Predict If Chemotherapy Will Benefit Patients Who Have Surgery for Early Stage Colon Cancer

Study Purpose

To learn if a ctDNA test done after your surgery for colon cancer is helpful to decide if you should receive chemotherapy.

Diagnosis

Patients with colon cancer that has been treated with surgery.

Eligibility

Confirmed stage IIA adenocarcinoma of the colon with at least 12 lymph nodes examined at the time of surgical resection.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group l: A blood samples will be tested for ctDNA. Patients will receive regular check-ups without any further treatment.
  • Group 2: A blood sample will be tested for ctDNA. If found, patients will receive chemotherapy for about 6 months. If not ctDNA is not found, patients will have no further treatment.

All patients will be seen 12 months after they joined the study and then every 6 months for the next 2 years.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase II
Methodist Health System Trial Code
NRG GI005
Related Specialties